Bicara治疗公司CFO于2026年3月售出股票, Bicara Therapeutics' CFO sold shares in March 2026 amid rising institutional interest and a "Moderate Buy" rating.

Bicara治疗学公司CFO Ivan Hyep在2026年3月出售了18 400股股票,包括3月3日13 555股18.22美元,将他的股份减少了8.53%,减至145 355股。 Bicara Therapeutics CFO Ivan Hyep sold 18,400 shares in March 2026, including 13,555 on March 3 at $18.22, reducing his stake by 8.53% to 145,355 shares. 该公司3月6日的股票交易额为18.50美元,52周交易额为7.80至19.71美元。 The company’s stock traded at $18.50 on March 6, with a 52-week range of $7.80 to $19.71. 分析员按照平均价格目标28.33美元对库存进行“机动购买”评级。 Analysts rate the stock a “Moderate Buy” with a $28.33 average price target. 机构所有权增加,塔研究资本和州街增加了股权. Institutional ownership increased, with Tower Research Capital and State Street boosting stakes. 该公司开发基于神经激素的疗法,包括用于产后抑郁症的PST-001和用于社会焦虑症和自闭症谱系障碍的PST-002。 The company develops neurohormone-based therapies, including PST-001 for postpartum depression and PST-002 for social anxiety and autism spectrum disorder.